Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019

Since the first biosimilar medicine, Omnitrope(®) (active substance somatropin) was approved in 2006, 53 biosimilars have been authorized in Spain. We estimate the budget impact of biosimilars in Spain from the perspective of the National Health System (NHS) over the period between 2009 and 2019. Dr...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Goñi, Manuel, Río-Álvarez, Isabel, Carcedo, David, Villacampa, Alba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069914/
https://www.ncbi.nlm.nih.gov/pubmed/33918795
http://dx.doi.org/10.3390/ph14040348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069914/
https://www.ncbi.nlm.nih.gov/pubmed/33918795
http://dx.doi.org/10.3390/ph14040348

Ejemplares similares